{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:23:17Z","timestamp":1780417397945,"version":"3.54.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Previous prospective outcome studies of statins have not provided any guidance on benefit-risk in patients with heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The primary objective is to determine whether rosuvastatin (10 mg) reduces the combined endpoint of cardiovascular mortality, non-fatal myocardial infarction or non-fatal stroke (time to first event). The first secondary endpoint is all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CORONA is a randomized, double-blind, placebo-controlled trial. Briefly, men and women, aged \u226560 years with chronic symptomatic systolic heart failure of ischemic aetiology and ejection fraction \u22640.40 (NYHA class III and IV) or \u22640.35 (NYHA class II) were eligible if they were not using or in need of cholesterol lowering drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean age was 73 years (n=5016; 24% women), with 37% in NYHA II and 62% in NYHA III, ejection fraction 0.31, total cholesterol 5.2 mmol\/L. Sixty percent have a history of myocardial infarction, 63% hypertension, and 30% diabetes. Patients are well treated for heart failure with 90% on loop or thiazide diuretics, 42% aldosterone antagonists, 91% ACE inhibitor or AT-I blocker, 75% beta-blockers, and 32% digitalis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CORONA is important for three main reasons: (1) A positive result is very important because of the high risk of the population studied, the increasing prevalence of elderly patients with chronic symptomatic systolic heart failure in our society, and the health economic issues involved. (2) If negative, new mechanistic questions about heart failure have to be raised. (3) If neutral we can avoid unnecessary polypharmacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ejheart.2005.09.005","type":"journal-article","created":{"date-parts":[[2005,10,18]],"date-time":"2005-10-18T07:21:09Z","timestamp":1129620069000},"page":"1059-1069","source":"Crossref","is-referenced-by-count":120,"title":["A Statin in the Treatment of Heart Failure? Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA): Study Design and Baseline Characteristics"],"prefix":"10.1093","volume":"7","author":[{"given":"John","family":"Kjekshus","sequence":"first","affiliation":[{"name":"Department of Cardiology, Rikshospitalet University Hospital, University of Oslo , Sognsvannsveien 20, Oslo, 0027 ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dunselman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ampia Hospital , Breda ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Blideskog","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D , M\u00f6lndal ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Eskilson","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D , M\u00f6lndal ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5ke","family":"Hjalmarson","sequence":"additional","affiliation":[{"name":"Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital , G\u00f6teborg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Western Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Waagstein","sequence":"additional","affiliation":[{"name":"Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital , G\u00f6teborg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Wedel","sequence":"additional","affiliation":[{"name":"Nordic School of Public Health , G\u00f6teborg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wessman","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D , M\u00f6lndal ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wikstrand","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D , M\u00f6lndal ,","place":["Sweden"]},{"name":"Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital , G\u00f6teborg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,7,27]]},"reference":[{"key":"2026020203565771500_ejhf2005-09-005-bib-0001","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0002","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0003","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0004","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"N Engl J Med"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0005","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"MRC\/BHF Heart Protection Study Group","year":"2002","journal-title":"Lancet"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0007","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care, the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0008","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0009","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have an average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0010","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0011","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0735-1097(02)01827-2","article-title":"Statins and chronic heart failure: do we need a large-scale outcome trial=","volume":"39","author":"Krum","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0012","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00392-005-0210-9","article-title":"Heart failure and statins\u2014why do we need a clinical trial=","volume":"94","author":"B\u00f6hm","year":"2005","journal-title":"Z Kardiol"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(97)04430-9","article-title":"Total cholesterol and risk of mortality in the oldest old","volume":"350","author":"Weverling-Rijnsburger","year":"1997","journal-title":"Lancet"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0014","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000006785","article-title":"Low serum cholesterol levels predict high perioperative mortality in patients supported by a left-ventricular assist system","volume":"89","author":"Richartz","year":"1998","journal-title":"Cardiology"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0002-9149(98)00334-8","article-title":"Skin anergy in advanced chronic heart failure secondary to either ischaemic or idiopathic dilated cardiomyopathy","volume":"82","author":"Vredevoe","year":"1998","journal-title":"Am J Cardiol"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0016","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1054\/jcaf.2002.0804216","article-title":"Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure","volume":"8","author":"Horwich","year":"2002","journal-title":"J Card Fail"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0017","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.jacc.2003.07.016","article-title":"The relationship between cholesterol and survival in patients with chronic heart failure","volume":"42","author":"Rauchhaus","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0018","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/S0140-6736(98)09286-1","article-title":"Endotoxin and immune activation in chronic heart failure: a prospective cohort study","volume":"353","author":"Niebauer","year":"1999","journal-title":"Lancet"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0019","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0167-5273(00)00224-2","article-title":"Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure","volume":"76","author":"Rauchhaus","year":"2000","journal-title":"Int J Cardiol"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0020","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(00)02690-8","article-title":"The endotoxin\u2013lipoprotein hypothesis","volume":"356","author":"Rauchhaus","year":"2000","journal-title":"Lancet"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0021","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/S0098-2997(97)00014-9","article-title":"Dose-related decrease of serum co-enzyme Q10 during treatment with HMG-CoA reductase inhibitors","volume":"18","author":"Mortensen","year":"1997","journal-title":"Mol Aspects Med"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0022","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/biof.5520180212","article-title":"The clinical use of HMGCoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications","volume":"18","author":"Langsjoen","year":"2003","journal-title":"BioFactors"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0023","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjcard.2004.07.121","article-title":"Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction","volume":"94","author":"Silver","year":"2004","journal-title":"Am J Cardiol"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0024","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archneur.61.6.889","article-title":"Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke","volume":"61","author":"Rundek","year":"2004","journal-title":"Arch Neurol"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0026","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0027","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosis.2004.01.009","article-title":"Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages","volume":"174","author":"Furman","year":"2004","journal-title":"Atherosclerosis"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0028","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1472-8206.2004.00286_4.x","article-title":"Effect of statins on macrophage activation after platelet phagocytosis","volume":"19","author":"Jans","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0029","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(96)05190-2","article-title":"Statins do more than just lower cholesterol","volume":"348","author":"Vaughan","year":"1996","journal-title":"Lancet"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/B978-0-7216-0380-3.50013-2","volume-title":"Statins: understanding clinical use","author":"Wolfrum","year":"2004"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0031","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0735-1097(00)00787-7","article-title":"Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients","volume":"36","author":"De Sutter","year":"2000","journal-title":"JACC"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0032","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0735-1097(03)00498-4","article-title":"Are lipid-lowering drugs also antiarrhythmic drugs= An analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial","volume":"42","author":"Mitchell","year":"2003","journal-title":"JACC"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0033","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/eurheartj\/ehi204","article-title":"Guidelines for the diagnosis and treatment of chronic heart failure","volume":"26","author":"Remme","year":"2005","journal-title":"Eur Heart J"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0034","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ejheart.2004.03.001","article-title":"Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure","volume":"6","author":"Tavazzi","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0036","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1071-9164(97)90022-1","article-title":"The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease","volume":"3","author":"Kjekshus","year":"1997","journal-title":"J Card Fail"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0037","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.0000084539.58092.DE","article-title":"Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy","volume":"108","author":"Node","year":"2003","journal-title":"Circulation"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0038","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jacc.2003.07.049","article-title":"Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure","volume":"43","author":"Horwich","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0039","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archinte.165.1.62","article-title":"Statin use and survival outcomes in elderly patients with heart failure","volume":"165","author":"Ray","year":"2005","journal-title":"Arch Intern Med"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0040","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/01.CIR.102.6.611","article-title":"Acute coronary findings at autopsy in heart failure patients with sudden death. Results from the assessment of treatment with lisinopril and survival (ATLAS) trial","volume":"102","author":"Uretsky","year":"2000","journal-title":"Circulation"},{"key":"2026020203565771500_ejhf2005-09-005-bib-0041","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.amjmed.2005.02.010","article-title":"Recurrent infarction is the most common cause of death in patients with left ventricular dysfunction following myocardial infarction","volume":"118","author":"\u00d8rn","year":"2005","journal-title":"Am J Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ejheart.2005.09.005","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/7\/6\/1059\/66637850\/eurjhf_7_6_1059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/7\/6\/1059\/66637850\/eurjhf_7_6_1059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:57:08Z","timestamp":1770022628000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/7\/6\/1059\/8445098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2007,7,27]]},"published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ejheart.2005.09.005","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,10]]},"published":{"date-parts":[[2005,10,1]]}}}